Primary multivariate survival analysis: rituximab plus chemotherapy versus chemotherapy alone
| Variable/level . | Hazard ratio (95% CI) (n = 1721) . |
|---|---|
| Initial infused therapy | |
| Chemotherapy alone | Reference |
| Rituximab plus chemotherapy | 0.75 (0.62-0.91) |
| Age, y | |
| 66-69 | Reference |
| 70-74 | 1.35 (1.07-1.70) |
| 75-79 | 1.62 (1.29-2.04) |
| ≥ 80 | 2.31 (1.85-2.90) |
| Sex | |
| Female | Reference |
| Male | 1.34 (1.17-1.53) |
| Race/ethnicity | |
| White | Reference |
| Black | 1.32 (1.00-1.74) |
| Hispanic | 1.12 (0.79-1.59) |
| Other | 0.93 (0.59-1.45) |
| Stage | |
| Not advanced | Reference |
| Advanced | 1.40 (1.22-1.60) |
| NCI comorbidity score | |
| 0 | Reference |
| 1 | 1.09 (0.93-1.29) |
| 2 | 1.16 (0.92-1.46) |
| ≥ 3 | 1.44 (1.06-1.94) |
| Variable/level . | Hazard ratio (95% CI) (n = 1721) . |
|---|---|
| Initial infused therapy | |
| Chemotherapy alone | Reference |
| Rituximab plus chemotherapy | 0.75 (0.62-0.91) |
| Age, y | |
| 66-69 | Reference |
| 70-74 | 1.35 (1.07-1.70) |
| 75-79 | 1.62 (1.29-2.04) |
| ≥ 80 | 2.31 (1.85-2.90) |
| Sex | |
| Female | Reference |
| Male | 1.34 (1.17-1.53) |
| Race/ethnicity | |
| White | Reference |
| Black | 1.32 (1.00-1.74) |
| Hispanic | 1.12 (0.79-1.59) |
| Other | 0.93 (0.59-1.45) |
| Stage | |
| Not advanced | Reference |
| Advanced | 1.40 (1.22-1.60) |
| NCI comorbidity score | |
| 0 | Reference |
| 1 | 1.09 (0.93-1.29) |
| 2 | 1.16 (0.92-1.46) |
| ≥ 3 | 1.44 (1.06-1.94) |
Patients using rituximab monotherapy are excluded. Models are also adjusted for potential confounding from year of infusion, education, poverty, and metropolitan statistical area size.